Ambulatory Peritoneal Dialysis
Kluwer Academic / Plenum Publishers (Verlag)
978-0-306-43351-1 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
At that time, it was deemed appropriate to form a more organized group and the International Society for Peritoneal Dialy- sis was founded. One of the first actions of the Society was to choose from among several applicants Dr.
I. Status of the Art.- 1. The Role of Cholesterol and Lipids in the Atherogenicity of Continuous Ambulatory Peritoneal Dialysis Patients: Update 1990.- 2. Erythropoietin in Continuous Ambulatory Peritoneal Dialysis Patients, 1990: Benefits of the Subcutaneous Route in the First U. S. Experience.- 3. Solving the Major Problems of Continuous Ambulatory Peritoneal Dialysis.- 4. Functional and Histological Changes of Peritoneal Membrane in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 5. Where Are We Going?.- II. Physiology, Pharmacology, and Morphology.- 6. Peritoneal Ultrafiltration: Less Efficient with Prolonged Dwell or Excessive Dialysate Dextrose.- 7. Neostigmine Increases Net Ultrafiltration and Solute Clearances in Peritoneal Dialysis by Reducing Lymphatic Absorption.- 8. Phosphatidylcholine Increases Ultrafiltration in Continuous Ambulatory Peritioneal Dialysis Patients.- 9. Effect of Cationic Molecules on the Permeability of the Mesothelium in Vitro.- 10. Phosphatidylcholine: A Physiological Modulator of the Peritoneal Membrane.- 11. Ultrafiltration Loss in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Intraperitoneal Therapy with Calcium Antagonists.- 12. A Chemoattractant in Peritoneal Effluent from Continuous Ambulatory Peritoneal Dialysis Patients.- 13. The Isolation and Culture of Human Mesothelial Cells: Characterization of Cyclooxygenase Products.- 14. Beta-Blockers Induce Functional Changes That Potentially Injure the Peritoneum in Continuous Ambulatory Peritoneal Dialysis Patients.- 15. Loss of Mesothelial and Microvascular Fixed Anionic Charges during Murine Experimentally Induced Septic Peritonitis.- 16. Role of Blood Osmolality in the Regulation of Vasopressin Secretion in Continuous Ambulatory Peritoneal Dialysis Patients.- 17. Lymphatic Absorption in Continuous Ambulatory Peritoneal Dialysis Patients with Normal and High Transperitoneal Glucose Transport.- 18. The Kinetics of Ultrafiltration during Peritoneal Dialysis in Rats: The Role of Lymphatics.- 19. Dihydroergotamine Lowers Peritoneal Transfer Rates: A Hypovolemic Transport Decrease.- 20. Ultrafiltration Patterns of Dextran and Hydroxyethylstarch during Long-Dwell Peritoneal Dialysis Exchanges in Nonuremic Rats.- 21. Peritoneal Clearances, Ultrafiltration, and Diuresis in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 22. Effect of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on the Transport of Inhibitory Factors of Lymphocyte Proliferation Present in Uremic Serum.- 23. Methotrexate Influences Peritoneal Permeability.- 24. High Doses of Intraperitoneal Furosemide in Long-Dwell Exchange.- 25. Calcium Peritoneal Mass Transfer in Continuous Ambulatory Peritoneal Dialysis.- 26. Structural Changes in Peritoneal Vessels during Continuous Ambulatory Peritoneal Dialysis: A Model for the Study of Diabetic Microangiopathy.- 27. Mesothelial Hyperplasia after Chronic Intraperitoneal Fluid Administration: A Light Microscopy Study in the Rat.- 28. Mitogenic Effect of the Peritoneal Effluent on Mice Fibroblast Cultures in Continuous Ambulatory Peritoneal Dialysis Patients.- 29. Oxygen Metabolism of Peritoneal Phagocytes.- III. Nutrition Metabolism.- 30. The Nutritional Status of Long-Term CAPD Patients.- 31. Renal Osteodystrophy: Bone Mineral Density Loss and Recovery with Treatment.- 32. Bone Mineralization Defect in Continuous Ambulatory Peritoneal Dialysis Patients.- 33. Faster Energy Turnover in Peritoneal Dialysis.- IV. Technology.- 34. One-Year Experience with Swan-Neck Missouri 2 Catheter.- 35. Thallium 201 Myocardial Imaging in Continuous Ambulatory Peritoneal Dialysis Patients at High Risk of Coronary Artery Disease.- 36. Tidal Peritoneal Dialysis.- 37. Absorption of Inulin and High-Molecular-Weight Gelatin Isocyanate Solutions from Peritoneal Cavity of Rats.- 38. Technical Developments in Continuous Ambulatory Peritoneal Dialysis: Summary of Personal Experiences.- 39. The Use of Hyposmolar Glucose Polymer Solution in Continuous Ambulatory Peritoneal Dialysis: A Seven-Day Study.- 40. Loss of Ultrafiltration Capacity: Role of Plasticizers.- 41. Chronic Peritoneal Dialysis Using Curled Catheters.- V. Peritonitis.- 42. Immune Defense and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 43. Peritoneal Macrophages of Patients on Continuous Ambulatory Peritoneal Dialysis Show Alterations in Sensitivity and Secretion of Prostaglandins during Peritonitis.- 44. Interferon Abnormalities and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 45. Association of Staphylococcus aureus Nasal Carriage with Staphylococcus aureus Catheter Exit-Site Infections.- 46. Survival and Growth of Staphylococcus epidermidis within Phagocytes in Relation to Recurrent Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 47. Does Viral Infection Predispose to Peritonitis in Continuous Ambulatory Peritoneal Dialysis?.- 48. Peritonitis: The Most Serious Complication of Continuous Ambulatory Peritoneal Dialysis: Results of a Multi-Center Study.- 49. Generation and Release of Eicosanoids and Proteolytic Enzymes by Human Peritoneal Macrophages in Response to Staphylococcus epidermidis and the Calcium Ionophore A23187.- 50. Humoral and Cellular Host-Defense Factors and Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 51. Continuous Ambulatory Peritoneal Dialysis Host Defenses and Staphylococcus aureus: Role of Opsonins, Fibronectin, Fibrinogen, and Fibrin.- 52. Long-Term Experience with the Y-Connector in Peritonitis Prevention in Continuous Ambulatory Peritoneal Dialysis Patients.- 53. Inhibition of Binding of Escherichia coli to Human Peritoneal Macrophages by Peritoneal Effluent from Patients on Peritoneal Dialysis.- 54. Use of Exudate Smears for Diagnosis of Peritoneal Catheter Exit-Site Infection.- 55. Early Bacteriological Diagnosis of Continuous Ambulatory Peritoneal Dialysis Peritonitis with the Use of a Cy to centrifuge.- VI. Clinical Experience.- 56. USA CAPD Registry: 1987 Report Highlights.- 57. Multi-Center Study of Outcome of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients: A 4-Year Analysis.- 58. Wilkinson Peritoneal Membrane Function in Myeloma.- 59. Risk Factors and Outcome of Diabetics on Continuous Ambulatory Peritoneal Dialysis.- 60. Survival of the "Ideal"I. Status of the Art.- 1. The Role of Cholesterol and Lipids in the Atherogenicity of Continuous Ambulatory Peritoneal Dialysis Patients: Update 1990.- 2. Erythropoietin in Continuous Ambulatory Peritoneal Dialysis Patients, 1990: Benefits of the Subcutaneous Route in the First U. S. Experience.- 3. Solving the Major Problems of Continuous Ambulatory Peritoneal Dialysis.- 4. Functional and Histological Changes of Peritoneal Membrane in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 5. Where Are We Going?.- II. Physiology, Pharmacology, and Morphology.- 6. Peritoneal Ultrafiltration: Less Efficient with Prolonged Dwell or Excessive Dialysate Dextrose.- 7. Neostigmine Increases Net Ultrafiltration and Solute Clearances in Peritoneal Dialysis by Reducing Lymphatic Absorption.- 8. Phosphatidylcholine Increases Ultrafiltration in Continuous Ambulatory Peritioneal Dialysis Patients.- 9. Effect of Cationic Molecules on the Permeability of the Mesothelium in Vitro.- 10. Phosphatidylcholine: A Physiological Modulator of the Peritoneal Membrane.- 11. Ultrafiltration Loss in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Intraperitoneal Therapy with Calcium Antagonists.- 12. A Chemoattractant in Peritoneal Effluent from Continuous Ambulatory Peritoneal Dialysis Patients.- 13. The Isolation and Culture of Human Mesothelial Cells: Characterization of Cyclooxygenase Products.- 14. Beta-Blockers Induce Functional Changes That Potentially Injure the Peritoneum in Continuous Ambulatory Peritoneal Dialysis Patients.- 15. Loss of Mesothelial and Microvascular Fixed Anionic Charges during Murine Experimentally Induced Septic Peritonitis.- 16. Role of Blood Osmolality in the Regulation of Vasopressin Secretion in Continuous Ambulatory Peritoneal Dialysis Patients.- 17. Lymphatic Absorption in Continuous Ambulatory Peritoneal Dialysis Patients with Normal and High Transperitoneal Glucose Transport.- 18. The Kinetics of Ultrafiltration during Peritoneal Dialysis in Rats: The Role of Lymphatics.- 19. Dihydroergotamine Lowers Peritoneal Transfer Rates: A Hypovolemic Transport Decrease.- 20. Ultrafiltration Patterns of Dextran and Hydroxyethylstarch during Long-Dwell Peritoneal Dialysis Exchanges in Nonuremic Rats.- 21. Peritoneal Clearances, Ultrafiltration, and Diuresis in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 22. Effect of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on the Transport of Inhibitory Factors of Lymphocyte Proliferation Present in Uremic Serum.- 23. Methotrexate Influences Peritoneal Permeability.- 24. High Doses of Intraperitoneal Furosemide in Long-Dwell Exchange.- 25. Calcium Peritoneal Mass Transfer in Continuous Ambulatory Peritoneal Dialysis.- 26. Structural Changes in Peritoneal Vessels during Continuous Ambulatory Peritoneal Dialysis: A Model for the Study of Diabetic Microangiopathy.- 27. Mesothelial Hyperplasia after Chronic Intraperitoneal Fluid Administration: A Light Microscopy Study in the Rat.- 28. Mitogenic Effect of the Peritoneal Effluent on Mice Fibroblast Cultures in Continuous Ambulatory Peritoneal Dialysis Patients.- 29. Oxygen Metabolism of Peritoneal Phagocytes.- III. Nutrition Metabolism.- 30. The Nutritional Status of Long-Term CAPD Patients.- 31. Renal Osteodystrophy: Bone Mineral Density Loss and Recovery with Treatment.- 32. Bone Mineralization Defect in Continuous Ambulatory Peritoneal Dialysis Patients.- 33. Faster Energy Turnover in Peritoneal Dialysis.- IV. Technology.- 34. One-Year Experience with Swan-Neck Missouri 2 Catheter.- 35. Thallium 201 Myocardial Imaging in Continuous Ambulatory Peritoneal Dialysis Patients at High Risk of Coronary Artery Disease.- 36. Tidal Peritoneal Dialysis.- 37. Absorption of Inulin and High-Molecular-Weight Gelatin Isocyanate Solutions from Peritoneal Cavity of Rats.- 38. Technical Developments in Continuous Ambulatory Peritoneal Dialysis: Summary of Personal Experiences.- 39. The Use of Hyposmolar Glucose Polymer Solution in Continuous Ambulatory Peritoneal Dialysis: A Seven-Day Study.- 40. Loss of Ultrafiltration Capacity: Role of Plasticizers.- 41. Chronic Peritoneal Dialysis Using Curled Catheters.- V. Peritonitis.- 42. Immune Defense and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 43. Peritoneal Macrophages of Patients on Continuous Ambulatory Peritoneal Dialysis Show Alterations in Sensitivity and Secretion of Prostaglandins during Peritonitis.- 44. Interferon Abnormalities and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 45. Association of Staphylococcus aureus Nasal Carriage with Staphylococcus aureus Catheter Exit-Site Infections.- 46. Survival and Growth of Staphylococcus epidermidis within Phagocytes in Relation to Recurrent Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 47. Does Viral Infection Predispose to Peritonitis in Continuous Ambulatory Peritoneal Dialysis?.- 48. Peritonitis: The Most Serious Complication of Continuous Ambulatory Peritoneal Dialysis: Results of a Multi-Center Study.- 49. Generation and Release of Eicosanoids and Proteolytic Enzymes by Human Peritoneal Macrophages in Response to Staphylococcus epidermidis and the Calcium Ionophore A23187.- 50. Humoral and Cellular Host-Defense Factors and Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 51. Continuous Ambulatory Peritoneal Dialysis Host Defenses and Staphylococcus aureus: Role of Opsonins, Fibronectin, Fibrinogen, and Fibrin.- 52. Long-Term Experience with the Y-Connector in Peritonitis Prevention in Continuous Ambulatory Peritoneal Dialysis Patients.- 53. Inhibition of Binding of Escherichia coli to Human Peritoneal Macrophages by Peritoneal Effluent from Patients on Peritoneal Dialysis.- 54. Use of Exudate Smears for Diagnosis of Peritoneal Catheter Exit-Site Infection.- 55. Early Bacteriological Diagnosis of Continuous Ambulatory Peritoneal Dialysis Peritonitis with the Use of a Cy to centrifuge.- VI. Clinical Experience.- 56. USA CAPD Registry: 1987 Report Highlights.- 57. Multi-Center Study of Outcome of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients: A 4-Year Analysis.- 58. Wilkinson Peritoneal Membrane Function in Myeloma.- 59. Risk Factors and Outcome of Diabetics on Continuous Ambulatory Peritoneal Dialysis.- 60. Survival of the "Ideal"I. Status of the Art.- 1. The Role of Cholesterol and Lipids in the Atherogenicity of Continuous Ambulatory Peritoneal Dialysis Patients: Update 1990.- 2. Erythropoietin in Continuous Ambulatory Peritoneal Dialysis Patients, 1990: Benefits of the Subcutaneous Route in the First U. S. Experience.- 3. Solving the Major Problems of Continuous Ambulatory Peritoneal Dialysis.- 4. Functional and Histological Changes of Peritoneal Membrane in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 5. Where Are We Going?.- II. Physiology, Pharmacology, and Morphology.- 6. Peritoneal Ultrafiltration: Less Efficient with Prolonged Dwell or Excessive Dialysate Dextrose.- 7. Neostigmine Increases Net Ultrafiltration and Solute Clearances in Peritoneal Dialysis by Reducing Lymphatic Absorption.- 8. Phosphatidylcholine Increases Ultrafiltration in Continuous Ambulatory Peritioneal Dialysis Patients.- 9. Effect of Cationic Molecules on the Permeability of the Mesothelium in Vitro.- 10. Phosphatidylcholine: A Physiological Modulator of the Peritoneal Membrane.- 11. Ultrafiltration Loss in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Intraperitoneal Therapy with Calcium Antagonists.- 12. A Chemoattractant in Peritoneal Effluent from Continuous Ambulatory Peritoneal Dialysis Patients.- 13. The Isolation and Culture of Human Mesothelial Cells: Characterization of Cyclooxygenase Products.- 14. Beta-Blockers Induce Functional Changes That Potentially Injure the Peritoneum in Continuous Ambulatory Peritoneal Dialysis Patients.- 15. Loss of Mesothelial and Microvascular Fixed Anionic Charges during Murine Experimentally Induced Septic Peritonitis.- 16. Role of Blood Osmolality in the Regulation of Vasopressin Secretion in Continuous Ambulatory Peritoneal Dialysis Patients.- 17. Lymphatic Absorption in Continuous Ambulatory Peritoneal Dialysis Patients with Normal and High Transperitoneal Glucose Transport.- 18. The Kinetics of Ultrafiltration during Peritoneal Dialysis in Rats: The Role of Lymphatics.- 19. Dihydroergotamine Lowers Peritoneal Transfer Rates: A Hypovolemic Transport Decrease.- 20. Ultrafiltration Patterns of Dextran and Hydroxyethylstarch during Long-Dwell Peritoneal Dialysis Exchanges in Nonuremic Rats.- 21. Peritoneal Clearances, Ultrafiltration, and Diuresis in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 22. Effect of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on the Transport of Inhibitory Factors of Lymphocyte Proliferation Present in Uremic Serum.- 23. Methotrexate Influences Peritoneal Permeability.- 24. High Doses of Intraperitoneal Furosemide in Long-Dwell Exchange.- 25. Calcium Peritoneal Mass Transfer in Continuous Ambulatory Peritoneal Dialysis.- 26. Structural Changes in Peritoneal Vessels during Continuous Ambulatory Peritoneal Dialysis: A Model for the Study of Diabetic Microangiopathy.- 27. Mesothelial Hyperplasia after Chronic Intraperitoneal Fluid Administration: A Light Microscopy Study in the Rat.- 28. Mitogenic Effect of the Peritoneal Effluent on Mice Fibroblast Cultures in Continuous Ambulatory Peritoneal Dialysis Patients.- 29. Oxygen Metabolism of Peritoneal Phagocytes.- III. Nutrition Metabolism.- 30. The Nutritional Status of Long-Term CAPD Patients.- 31. Renal Osteodystrophy: Bone Mineral Density Loss and Recovery with Treatment.- 32. Bone Mineralization Defect in Continuous Ambulatory Peritoneal Dialysis Patients.- 33. Faster Energy Turnover in Peritoneal Dialysis.- IV. Technology.- 34. One-Year Experience with Swan-Neck Missouri 2 Catheter.- 35. Thallium 201 Myocardial Imaging in Continuous Ambulatory Peritoneal Dialysis Patients at High Risk of Coronary Artery Disease.- 36. Tidal Peritoneal Dialysis.- 37. Absorption of Inulin and High-Molecular-Weight Gelatin Isocyanate Solutions from Peritoneal Cavity of Rats.- 38. Technical Developments in Continuous Ambulatory Peritoneal Dialysis: Summary of Personal Experiences.- 39. The Use of Hyposmolar Glucose Polymer Solution in Continuous Ambulatory Peritoneal Dialysis: A Seven-Day Study.- 40. Loss of Ultrafiltration Capacity: Role of Plasticizers.- 41. Chronic Peritoneal Dialysis Using Curled Catheters.- V. Peritonitis.- 42. Immune Defense and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 43. Peritoneal Macrophages of Patients on Continuous Ambulatory Peritoneal Dialysis Show Alterations in Sensitivity and Secretion of Prostaglandins during Peritonitis.- 44. Interferon Abnormalities and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 45. Association of Staphylococcus aureus Nasal Carriage with Staphylococcus aureus Catheter Exit-Site Infections.- 46. Survival and Growth of Staphylococcus epidermidis within Phagocytes in Relation to Recurrent Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 47. Does Viral Infection Predispose to Peritonitis in Continuous Ambulatory Peritoneal Dialysis?.- 48. Peritonitis: The Most Serious Complication of Continuous Ambulatory Peritoneal Dialysis: Results of a Multi-Center Study.- 49. Generation and Release of Eicosanoids and Proteolytic Enzymes by Human Peritoneal Macrophages in Response to Staphylococcus epidermidis and the Calcium Ionophore A23187.- 50. Humoral and Cellular Host-Defense Factors and Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 51. Continuous Ambulatory Peritoneal Dialysis Host Defenses and Staphylococcus aureus: Role of Opsonins, Fibronectin, Fibrinogen, and Fibrin.- 52. Long-Term Experience with the Y-Connector in Peritonitis Prevention in Continuous Ambulatory Peritoneal Dialysis Patients.- 53. Inhibition of Binding of Escherichia coli to Human Peritoneal Macrophages by Peritoneal Effluent from Patients on Peritoneal Dialysis.- 54. Use of Exudate Smears for Diagnosis of Peritoneal Catheter Exit-Site Infection.- 55. Early Bacteriological Diagnosis of Continuous Ambulatory Peritoneal Dialysis Peritonitis with the Use of a Cy to centrifuge.- VI. Clinical Experience.- 56. USA CAPD Registry: 1987 Report Highlights.- 57. Multi-Center Study of Outcome of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients: A 4-Year Analysis.- 58. Wilkinson Peritoneal Membrane Function in Myeloma.- 59. Risk Factors and Outcome of Diabetics on Continuous Ambulatory Peritoneal Dialysis.- 60. Survival of the "Ideal" Continuous Ambulatory Peritoneal Dialysis Patient.- 61. Efficacy of Hepatitis B Vaccine in Continuous Ambulatory Peritoneal Dialysis Patients Is Influenced by Blood Transfusion.- 62. Stable Continuous Ambulatory Peritoneal Dialysis Patients Assess the Suitability of New Candidates.- 63. Individualization of Exchange Volume to Optimize Continuous Ambulatory Peritoneal Dialysis.- 64. Postural Hypotension with Glucose Ingestion in Patients on Continuous Ambulatory Peritoneal Dialysis.- 65. Impact of Increasing Intraperitoneal Volume on Left Ventricular Function in Continuous Ambulatory Peritoneal Dialysis Patients.- 66. Continuous Cycling Peritoneal Dialysis: Wet Is Better Than Dry.- 67. Comparative Evaluation of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis: A Multi-Center Study.- 68. Continuous Ambulatory Peritoneal Dialysis for the AIDS Patient.- 69. Comparative Study of Muzolimine and Furosemide in Continuous Ambulatory Peritoneal Dialysis Patients.- 70. Successful Joint Care of Continuous Ambulatory Peritoneal Dialysis Patients with Two District General Hospitals.- 71. The Benefits of Long-Life Tubing in Continuous Ambulatory Peritoneal Dialysis.- 72. Effect of Protein or Amino Acid Supplementation on the Nutritional Status of Patients on Continuous Ambulatory Peritoneal Dialysis.- 73. New Strategy following Peritoneal Catheter Implantation in Continuous Ambulatory Peritoneal Dialysis.- 74. Treatment of Refractory Congestive Heart Failure by Continuous Ambulatory Peritoneal Dialysis.- 75. Vitamin Deficiencies in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Supplementation.- 76. Leakage of Dialysate across the Diaphragm.- 77. Continuous Ambulatory Peritoneal Dialysis - An Adequate Therapy in Developing Countries.- VII. Experience in Infants and Children.- 78. Acute Peritoneal Dialysis in Premature and Newborn Infants.- 79. Peritoneal Dialysis in Acute Renal Failure in the Neonate: Limits and Complications.- 80. The Optimal Dialysis Regimen for Children Undergoing Different Continuous Cycling Peritoneal Dialysis Protocols.- 81. Intracellular Amino Acids in Children on Continuous Ambulatory Peritoneal Dialysis.- 82. Efficiency of High-Volume Continuous Ambulatory Peritoneal Dialysis in Children.- 83. Outpatient Cycler Peritoneal Dialysis for Home Failure, Hemodialysis Failure, AV Access Failure, and Cardiovascular Instability.- Contributors.
| Zusatzinfo | biography |
|---|---|
| Verlagsort | Dordrecht |
| Sprache | englisch |
| Gewicht | 760 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete |
| ISBN-10 | 0-306-43351-6 / 0306433516 |
| ISBN-13 | 978-0-306-43351-1 / 9780306433511 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
